This is a Phase 3 master study to evaluate the safety, tolerability, and immunogenicity of RSVpreF subunit vaccine in adults at High Risk of Severe RSV Disease.
Substudy A Design:
This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study that will assess the safety, tolerability, and immunogenicity of Pfizer’s RSVpreF in adults 18 to <60 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions.
Substudy B Design:
This is a Phase 3, single-arm, open-label, multicenter study that will assess the safety, tolerability, and immunogenicity of Pfizer’s RSVpreF in immunocompromised adults.
The George Washington University is seeking volunteers for an RSV vaccine clinical trial who are:
Substudy A
ENROLLMENT CLOSED
Substudy B
- At least 60 years old
- Are immunocompromised, which may include:
- Non-small cell lung cancer (NSCLC) and receiving treatment
- Organ transplant recipient
- On hemodialysis
- On therapy for autoimmune disorders (such as inflammatory bowel disease or type of arthritis)
- Have never received an investigational RSV vaccine